3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
157
Lung Neoplasms
73
Small Cell Lung Carcinoma
52
Neoplasms
8
Melanoma
8
Carcinoma, Renal Cell
7
Squamous Cell Carcinoma of Head and Neck
6
Mesothelioma, Malignant
6
Mesothelioma
6
Colorectal Neoplasms
6
Carcinoma
6
Breast Neoplasms
6
Stomach Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Hepatocellular
5
Triple Negative Breast Neoplasms
4
Respiratory Tract Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Thoracic Neoplasms
3
Respiratory Tract Diseases
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Esophageal Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Bronchogenic
3
Bronchial Neoplasms
3
Adenocarcinoma of Lung
3
Interventions
pembrolizumab
4
Pemetrexed
4
Carboplatin
4
Gemcitabine
3
Bevacizumab
3
tusamitamab ravtansine
2
Vinorelbine
2
Ramucirumab
2
Erlotinib Hydrochloride
2
Docetaxel
2
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
vistusertib
1
vandetanib
1
telomerase reverse transcriptase p572Y, human
1
spartalizumab
1
sotorasib
1
sintilimab
1
olaparib
1
necitumumab
1
icotinib
1
durvalumab
1
dacomitinib
1
capivasertib
1
aumolertinib
1
Radiosurgery
1
Platinum
1
Paclitaxel
1
MLN 8237
1
LY3023414
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-small Cell Lung Cancer Metastatic
×
durvalumab
×
Thoracic
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled